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ABSTRACT 1 
 2 
Mass spectrometry-based metabolomic methods enable simultaneous profiling of 3 
hundreds of salivary metabolites, and may be useful to diagnose a wide range of 4 
diseases using saliva. However, few studies have evaluated the effects of 5 
physiological or environmental factors on salivary metabolomic profiles. Therefore, 6 
we used capillary electrophoresis-mass spectrometry to analyze saliva metabolite 7 
profiles in 155 subjects with reasonable oral hygiene, and examined the effects of 8 
physiological and environmental factors on the metabolite profiles. Overall, 257 9 
metabolites were identified and quantified. The global profiles and individual 10 
metabolites were evaluated by principle component analysis and univariate tests, 11 
respectively. Collection method, collection time, sex, body mass index, and smoking 12 
affected the global metabolite profiles. However, age also contributed to the bias in 13 
sex and collection time. The profiles were relatively unaffected by other 14 
parameters, such as alcohol consumption and smoking, tooth brushing, or the use 15 
of medications or nutritional supplements. Temporomandibular joint disorders 16 
had relatively greater effects on salivary metabolites than other dental 17 
abnormalities (e.g., stomatitis, tooth alignment, and dental caries). These findings 18 
 4 
provide further insight into the diversity and stability of salivary metabolomic 1 
profiles, as well as the generalizability of disease-specific biomarkers. 2 
 3 
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1 Introduction 1 
Saliva is a readily accessible and informative biofluid that is ideal for the early detection 2 
of many diseases, including periodontitis, hepatitis, human immunodeficiency virus, 3 
viral hepatitis, and cancer (Lee et al., 2009). It can also be used to monitor the 4 
concentrations of various drugs, including marijuana, cocaine, and phencyclidine 5 
(Schramm et al., 1992). Advantages of using saliva as a diagnostic tool are that it is easy 6 
and noninvasive to collect, associated with less discomfort than venipuncture, and does 7 
not entail privacy issues, unlike urine collection (Lee and Wong, 2009). Consequently, 8 
omics technologies, including transcriptomics and proteomics, have been used for 9 
high-throughput identification of disease-associated salivary biomarkers, to better 10 
understand the complex biology of the oral cavity, and facilitate the diagnosis of 11 
diseases in and remote from the oral cavity (Grant, 2012, Spielmann and Wong, 2011).  12 
Metabolomic profiles lying downstream of the regulatory information derived 13 
from other omics data are thought to directly reflect physical phenotypes. They also 14 
provide a new opportunity to use saliva for the diagnosis of diseases, including 15 
periodontal diseases, leukoplakia, and oral and systemic cancers (Aimetti et al., 2011, 16 
Barnes et al., 2011, Sugimoto et al., 2010, Wei et al., 2010, Yan et al., 2008). However, 17 
salivary metabolomic profiles may be affected by physiological, pathological, and 18 
 6 
environmental factors, independently of a disease. Thus, the pioneering metabolomics 1 
studies used 
1
H-nuclear magnetic resonance (NMR) to evaluate the associations 2 
between salivary metabolites and parameters of interest, including saliva collection 3 
method (stimulated and unstimulated), sex, smoking, time of collection (i.e., diurnal 4 
variation), body mass index (BMI), blood pressure, and dietary intake (Silwood et al., 5 
2002, Walsh et al., 2006, Takeda et al., 2009). More recently, profiling technologies 6 
have switched to hyphenated mass spectrometry (MS), which allows simultaneous 7 
quantification of a larger number and a wider range of metabolites compared with 8 
NMR-based methods (Barnes et al., 2011, Sugimoto et al., 2010). However, to our 9 
knowledge, the effects of physiological, pathological, and environmental factors on the 10 
diversity and stability of MS-based salivary metabolomic profiles have not been 11 
reported. 12 
In this study, we used capillary electrophoresis-time-of-flight mass spectrometry 13 
(CE-TOFMS) (Soga et al., 2006) to detect and quantify charged metabolites in saliva 14 
obtained from healthy young subjects with reasonable oral hygiene (i.e., the subjects 15 
were without periodontal disease or gingival inflammation at least). We focused on 16 
females in this study because of the complexity of endogenous metabolism attributable 17 
to female hormones, although we also investigated sex-specific differences as a pilot 18 
 7 
study. The profiles were analyzed according to relevant physiological and 1 
environmental factors to better understand the metabolomic characteristics of saliva. 2 
 3 
2. Materials and Methods 4 
2.1. Subjects and saliva collection 5 
This study was approved by the Ethics Committee of the Kanagawa Dental College. 6 
Volunteers were recruited from Kanagawa Dental College and Yokohama School of 7 
Dental Technology. Written, informed consent was obtained from all patients and from 8 
volunteers who agreed to provide saliva samples. Physiological, clinical, and lifestyle 9 
characteristics were recorded by questionnaires. Oral cavity disorders included 10 
stomatitis, glossalgia, xerostomia, and bruxism. The number of dental caries, presence 11 
of periodontitis, and temporomandibular joint disorder (TMD) were also determined. 12 
No patient with periodontal disease or glossalgia was included. The comparative study 13 
design is presented in Fig. 1. 14 
Saliva was collected at the same time in each subject (11:40 and 16:00), after 15 
fasting for ≥ 1 h (n = 104) after breakfast or lunch. The mean ± standard deviation (SD) 16 
age was 22.4 ± 4.4 years (range, 19–41 years) for the subjects whose saliva were 17 
collected at morning (n = 86, including 4 with missing values) and 21.0 ± 5.0 years 18 
 8 
(range, 18–27 years) for subjects whose saliva was collected in the afternoon (n = 18). 1 
Saliva samples were collected by the absorbent method using salivettes (Sarstedt Co. 2 
Ltd., Nümbrecht, Germany). Eighteen females provided saliva samples using both the 3 
absorbent and the passive drool methods. During collection, the tube was kept on ice, 4 
and the samples were immediately stored at –80°C. Only saliva samples used for 5 
comparisons between sex (24 females and 27 males) were collected at 16:00 on another 6 
day. The mean ± SD ages of these males and females were 21.8 ± 5.6 years (range, 7 
18–43 years; n = 24) and 23.7 ± 5.0 years (range, 18–36 years; n = 27), respectively. 8 
 9 
2.2. Metabolomic analysis 10 
Frozen saliva was thawed and centrifuged through a 5-kDa cutoff filter (Millipore, 11 
Bedford, MA) at 9,100×g for at least 2.5 h at 4C to remove macromolecules. Five 12 
microliters of Milli-Q water containing internal standards (2 mmol/l each of methionine 13 
sulfone, 2-[N-morpholino]-ethanesulfonic acid, D-camphor-10-sulfonic acid, 14 
3-aminopyrrolidine, and trimesate) was added to 45 μL of the filtrate and mixed. 15 
CE-TOFMS was used to simultaneously quantify charged metabolites in the positive 16 
and negative modes. Metabolites between 50 and 1,000 m/z were detected and matched 17 
with compounds in our standard library. The instrumental parameters and measurement 18 
 9 
conditions are described in the Supplementary Material and Methods. 1 
 2 
2.3. Data analysis 3 
Raw data were analyzed using our proprietary system, which detected all of the possible 4 
peaks, eliminated noise and redundant features, and generated the aligned data matrix 5 
(Sugimoto et al., 2010). Metabolite identification was conducted by matching the m/z 6 
values and the normalized migration times with those of our standard compounds. The 7 
concentrations of individual metabolites were calculated using internal and external 8 
standards, a typical workflow for CE-TOFMS data processing (Sugimoto et al., 2012b). 9 
Principal component analysis (PCA) was used to assess the diversity of the 10 
metabolomic profiles. Different numbers of individuals and metabolites were used in 11 
each PCA analysis. For example, to analyze the effects of smoking among saliva 12 
collected at morning (n = 86), samples from nonsmokers (n = 70) and smokers (n = 14) 13 
were used; the saliva samples with missing values for the parameter (n = 2) were 14 
eliminated. The metabolites whose concentrations were 0 in all saliva samples were also 15 
eliminated. Therefore, the number of metabolites included in the PCA differed 16 
depending on the comparison. 17 
Wilcoxon matched paired test and Wilcoxon’s test were used to analyze saliva 18 
 10 
collection method and the other characteristics, respectively. Values of P < 0.05 were 1 
considered statistically significant. To account for multiple testing, we calculated the 2 
q-value, a false discovery rate, for all P-values (Storey and Tibshirani, 2003, Broadhurst 3 
and Kell, 2006). Data analyses and visualization were conducted using R-software 4 
(2.14.0), JMP (9.0.2, SAS Institute, Cary, NC), and GraphPad Prism (Intuitive Software 5 
for Science, San Diego, CA). 6 
 7 
3. Results and Discussion 8 
3.1. Overview of metabolomic profiles 9 
CE-TOFMS detected and identified a total of 257 types of charged metabolite, with a 10 
mean ± SD of 141 ± 16 metabolites in each saliva sample. The PCA score plots are 11 
presented in Fig. 2 and Supplementary Fig. S1. Statistical significance of the difference 12 
between principal components 1 and 2 (PC1 and PC2), and the metabolites showing 13 
significant differences in concentrations are summarized in Table 1. Because many 14 
metabolites were significantly different between the samples collected in the morning 15 
and afternoon, and between samples collected using salivettes and the passive drool 16 
method, the associations of metabolomic profiles with other features were only 17 
evaluated using samples collected in the morning with a salivette. For individual 18 
 11 
analyses, the subjects were selected as appropriate; for example tooth brushing was 1 
analyzed in subjects who ate breakfast and did/did not brush their teeth (Fig. 1). The 2 
metabolites showing differences at P < 0.05 are listed in Supplementary Tables S1–S16. 3 
 4 
3.2. Saliva collection 5 
The collection method had a marked effect on metabolite profiles, as many metabolites 6 
showed significant differences between the two collection methods (Supplementary 7 
Table S1). PCA revealed that the first and second PC values were significantly different 8 
between saliva collected using salivettes and the passive drool method (P = 0.0451 and 9 
P = 0.0009) (Fig. 3a, Table 1). Most of the metabolites were widely distributed along 10 
the first PC axis of the loading plots with positive values (right side) without prominent 11 
clustering, although some metabolites, including urea, mucate, and riboflavin, had 12 
negative values (left side) (Fig. 3b). In contrast, along the second PC axis, 13 
approximately half of the metabolites had positive (upper side) and half had negative 14 
values (lower side) (Fig. 3b). As expected, the metabolites with the largest and smallest 15 
PC values showed opposite trends; for example, the concentrations of asparagine and 16 
agmatine were higher when collected using salivettes or the passive drool method, 17 
respectively (Fig. 3c). 18 
 12 
In a similarly designed study, Kozaki et al. found that melatonin concentrations 1 
were lower in saliva collected using a cotton swab compared with passively collected 2 
saliva (Kozaki et al., 2011). Because there is some physical contact between the cotton 3 
swab and the mouth, it is likely that collection with a cotton swab weakly stimulates the 4 
salivary gland. The concentrations of stimulated salivary metabolites were generally 5 
lower than those of unstimulated salivary metabolites (Takeda et al., 2009). However, 6 
that study used NMR and investigated only a few metabolites, whereas the metabolomic 7 
profiles observed here showed more complicated changes. Aberrant lipid and organic 8 
acid profiles have also been reported in saliva stimulated by chewing (Neyraud et al., 9 
2011). Collectively, these results indicate that adsorption of metabolites to a cotton swab 10 
complicates the differences in metabolites observed here.  11 
There were no significant differences in PC values between each collection time 12 
(Table 1). Except for two outliers, the metabolites in saliva collected in the afternoon 13 
congregated at the intersection of the PC1 and PC2 axes, unlike those of saliva collected 14 
in the morning (Supplementary Fig. S1a). Unlike the collection method, the amino acids, 15 
except for glutamic acids, were not significantly different between the two collection 16 
times (Supplementary Table S2). Previous studies have already demonstrated diurnal 17 
changes in the salivary metabolites of individual subjects (Bertram et al., 2009, Cooke 18 
 13 
et al., 2003). It was previously reported that the concentrations of amines, such as 1 
putrescine and cadaverine, were decreased in the afternoon (Cooke et al., 2003), but this 2 
was not observed in our profiles. One limitation of our study is that we compared saliva 3 
samples collected at two different times and from different individuals. Additionally, we 4 
did record the time each subject woke in the morning. Because we already know that the 5 
metabolomic profiles in blood show diurnal variation (Kasukawa et al. 2012, Minami et 6 
al., 2009), we should collect saliva samples from the same individuals and more 7 
frequently. Nevertheless, it is clear that salivary metabolomic profiles are sensitive to 8 
sampling time. Furthermore, inconsistences in sample collection may result in 9 
systematic bias in the metabolite profiles. 10 
 11 
3.3. Physiological parameters 12 
The effects of physiological parameters, including sex, BMI, and menstruation, were 13 
evaluated. The comparison between females (n = 24) and males (n = 27) showed clearly 14 
separated clusters in the PCA score plots (Fig. 2a) and significant differences in both 15 
PC1 and PC2 (Table 1). Notably, the concentrations of most of the amino acids were 16 
higher in females, including leucine, isoleucine, proline, and methionine (fold-change > 17 
5.0) (Supplementary Table S3). As discussed in earlier NMR-based metabolomics 18 
 14 
studies (Bertram et al., 2009, Takeda et al., 2009), the differences in blood metabolite 1 
concentrations between males and females are at least partly due to estrogen-related 2 
metabolism. Some differences in gene expression profiles in the parotid glands have 3 
also been reported between males and females (Srivastava et al., 2008), which may also 4 
contribute to the differences noted in our study. 5 
Saliva from subjects with a low BMI (< 18.73 kg/m
2
) showed significant 6 
differences in PC2 (P = 0.077) with eight upregulated metabolites and 14 7 
downregulated metabolites as compared with subjects with a BMI ≥ 18.73 kg/m2) 8 
(Table 1, Fig. 2b). By contrast, saliva from subjects with a BMI ≥ 21.00 kg/m2 showed 9 
no significant differences in PCs, and only four metabolites were downregulated as 10 
compared with subjects with a BMI < 21.00 kg/m
2
 (Supplementary Tables S4 and S5). 11 
The effects of BMI were much smaller than the diurnal variations in NMR-based 12 
profiles (Bertram et al., 2009). A total of 22 metabolites reached statistical significance 13 
at P < 0.05 and q < 0.5 in comparisons of saliva from subjects with BMI < 18.73 kg/m
2
 14 
versus subjects with BMI ≥ 18.73 kg/m2. 15 
Saliva collected from women during menstruation would be expected to show 16 
differences in female hormones. However, no significant difference was observed in the 17 
PC values. Only two metabolites, 4-amino-3-hydroxybutyrate (P < 0.05 and q < 0.5) 18 
 15 
and lipoamide (P < 0.05 and q ≥ 0.5), were significantly affected by menstruation (Table 1 
1, Supplementary Fig. S1b, Supplementary Table S6). Changes in amino acid and 2 
creatinine levels in blood and urea in the luteal phase have been reported (Wallace et al., 3 
2010). However, these changes were not observed in our study, suggesting that salivary 4 
metabolites are relatively unaffected by menstruation. 5 
 6 
3.4. Diet and tooth brushing 7 
The metabolite profiles of subjects who did/did not eat breakfast and of subjects who 8 
did/did not brush their teeth showed no significant differences in their PC values (Table 9 
1, Fig. 2c, Supplementary Fig. S1c). Only two amino acids, leucine and valine, were 10 
significantly increased, while serine was significantly decreased by consuming breakfast 11 
(P < 0.05, q < 0.5) (Supplementary Table S7). These changes in the amino acid profile, 12 
which were more pronounced compared with the effects of other factors, were 13 
inconsistent with the results of the following two studies. The salivary amino acid 14 
profiles were relatively constant, unlike the blood and urine levels after consumption of 15 
a high-protein meal (Brand et al., 1997). The increased amino acid concentrations 16 
observed after the intake of an amino acid supplement decreased to basal levels within 17 
10 min (Nakamura et al., 2010). The unchanged concentrations of putrescine (P = 0.59) 18 
 16 
and cadavarine (P = 0.76) measured after tooth brushing after breakfast were 1 
inconsistent with the time-course analysis of saliva metabolites (Cooke et al., 2003). 2 
These studies compared multiple saliva samples from individual subjects to eliminate 3 
inter-individual differences. Further studies are needed to confirm our observations in 4 
another cohort of subjects under controlled dietary conditions, including timing and 5 
meal content, which were not considered in the current study. 6 
 7 
3.5. Lifestyle habits 8 
Smoking had a significant effect on PC2, although visual inspection of the score plots 9 
showed no clear clusters (Table 1, Fig. 2d). As expected, saliva nicotine concentrations 10 
were much higher in smokers than in non-smokers (Supplementary Table S9).  11 
Purine metabolites, such as hypoxanthine and guanosine monophosphate (GMP), 12 
were also significantly increased in smokers (Supplementary Table S9). It was reported 13 
that hypoxanthine guanine phosphoribosyltransferase (HGPRT; 2.4.2.8) was markedly 14 
decreased in blood from smokers compared with non-smokers (Chang et al., 2005). This 15 
enzyme converts hypoxanthine to inosine monophosphate (IMP) and guanine to GMP. 16 
Therefore, increases in hypoxanthine/IMP and guanine/GMP are expected if salivary 17 
enzyme activity reflects that in blood. IMP was not detected in any saliva samples, 18 
 17 
while hypoxanthine was elevated in saliva (1.35-fold). However, GMP (1.57-fold) was 1 
increased to a greater extent than guanine (1.22-fold). Therefore, the regulation of these 2 
metabolites in saliva is more complicated than that in blood, and cannot be explained by 3 
the activity of HGPRT alone. 4 
Several molecules in the glycolysis pathway, including lactate (1.73-fold) and 5 
pyruvate (1.23-fold), were elevated in saliva from smokers, although not significantly. 6 
These results are consistent with those in the study by Takeda et al. (Takeda et al., 2009). 7 
Previous studies have also reported reduced salivary enzyme activities, including lactic 8 
dehydrogenase (LDH) and amylase (Nagler et al., 2000). These findings imply that the 9 
pyruvate/lactate ratio is elevated; however, our observation was inconsistent with this 10 
notion. By contrast, chronic cigarette smoking increased LDH activity in blood 11 
(Padmavathi et al., 2009). Therefore, altered LDH activity might provide only a small 12 
contribution to the elevated lactate level; instead, the secretion of lactate from the 13 
salivary gland might have a greater influence. 14 
Saliva from individuals who regularly consumed alcohol showed no significant 15 
differences in PC1 and PC2 (Table 1, Supplementary Fig. S1d, Supplementary Table 16 
S10) Thus, alcohol consumption did not seem to chronically affect salivary metabolites. 17 
Many medications and nutritional supplements are known to decrease or increase 18 
 18 
the rate of saliva secretion (Lukkari et al., 1997, Ryo et al., 2011). However, we found 1 
no significant differences in the concentrations of the identified metabolites in subjects 2 
who used medications (P = 0.987) or nutritional supplements (P = 0.3138) 3 
(Supplementary Fig. S2), nor were PC1 and PC2 significantly different (Table 1, 4 
Supplementary Figs. S1e, S1f). Only two metabolites were decreased in saliva from 5 
subjects who used medications (n =5, P < 0.05); however, the q-values were relatively 6 
large (> 0.95) (Supplementary Table S11). These results should be validated in a larger 7 
cohort because all of these subjects used different types of medications. Saliva from 8 
subjects who used nutritional supplements, including vitamin drops (n = 4) and black 9 
vinegar (n = 1), showed elevated glutarate concentrations (fold-change = 7.1), a 10 
common component of nutritional supplements (Kleber et al., 1979), as well as 11 
histamine (fold-change = 1.4) and 1-methylhistamine (fold-change = 2.4) 12 
(Supplementary Table S12). The salivary histamine concentration was reported to be a 13 
marker for periodontal disease in patients with diabetes (Venza et al., 2006). However, 14 
no subjects with periodontal disease were included in our study; therefore, the changes 15 
in the histamine pathway might be due to a factor that was not evaluated here. 16 
 17 
3.6. Oral conditions 18 
 19 
In terms of oral cavity conditions, we examined the effects of abnormalities of the oral 1 
cavity and tooth alignment, the number of dental caries, and TMD. PCA showed no 2 
significant differences in the PC1 or PC2 values in these cases (Table 1, Supplementary 3 
Tables S13–S16, Supplementary Fig. S1g–S1j) 4 
Several studies have shown metabolic abnormalities in subjects with dental caries. 5 
For example, the concentrations of arginine and lysine in stimulated parotid saliva were 6 
higher in subjects without caries than in those with caries (Van Wuyckhuyse et al., 7 
1995). Similarly, central carbon metabolism was reported to be abnormal in 8 
supragingival plaque and several oral bacterial species have been detected in subjects 9 
with dental caries (Takahashi et al., 2010). Therefore, we can expect abnormalities in 10 
salivary metabolomic profiles in patients with dental caries. Indeed, we found that 11 
arginine (fold-change = 1.1, P = 0.27) and lysine (fold-change = 1.57, P = 0.16) saliva 12 
concentrations were slightly elevated, although not significantly. Several metabolomics 13 
studies have investigated the changes in metabolites in subjects with periodontal 14 
diseases. For example, it was reported that the concentrations of metabolites in the 15 
purine degradation pathway were increased in gingival fluid in subjects with periodontal 16 
disease (Barnes et al., 2009); however, these metabolites, including hypoxanthine 17 
(fold-change = 0.97, P = 0.39), were unchanged in whole saliva in our study. Similarly, 18 
 20 
it was previously reported that saliva phenylalanine and valine concentrations were 1 
increased and pyruvate concentrations were decreased in subjects with periodontal 2 
disease (Aimetti et al., 2011); however, these changes were not observed in our study. 3 
Our observations suggest that these metabolite changes are specific to periodontal 4 
diseases, rather than dental caries. 5 
In the subject with TMD, the q-values for alanine and thymine were smaller than 6 
those for metabolites associated with other oral conditions (Supplementary Table S16). 7 
The P-value for PC2 in TMD (P = 0.1075) was much smaller than those for the PC 8 
values of other oral conditions, although these values were not statistically significant. 9 
These results indicate that TMD has a greater effect on saliva profiles compared with 10 
the other oral cavity parameters evaluated in this study. The effects of TMD on salivary 11 
metabolites were expected because patients with TMD have abnormal urinary amino 12 
acid profiles (McGregor et al., 2003) and elevated salivary cortisol levels (Da Silva 13 
Andrade et al., 2008). The increased oxidized glutathione concentration suggests the 14 
presence of severe oxidative stress in these patients. In fact, estrogen activates 15 
inflammation by inducing the proliferation and differentiation of macrophages in 16 
temporomandibular joint cellular elements (Galal et al., 2008). Only the increases in 17 
alanine concentrations (fold-change = 1.33, P = 0.0067) were consistently correlated 18 
 21 
with the concentrations of metabolites secreted from activated macrophages. By 1 
contrast, there were no increases in other metabolites that are abundantly secreted from 2 
macrophages in the saliva from subjects with TMD (Sugimoto et al., 2012c), which 3 
indicates that these changes are mainly derived from other mechanisms. Interestingly, 4 
salivary D-alanine was not derived from bacteria or food; instead, the submandibular 5 
gland and epithelial cells are the main sources of this metabolite, without transferring 6 
D-alanine from blood (Nagata et al., 2006). This suggests that D-alanine more clearly 7 
reflects the metabolic status of host cells in the oral cavity than other metabolites, which 8 
are secreted by multiple sources. However, our CE-MS method could not separate L- 9 
and D-alanine. Therefore, further studies are needed to identify the sources of these 10 
metabolites in TMD to understand the underlying mechanisms. 11 
 12 
3.7. Other factors and limitations 13 
Aging may also affect salivary metabolomic profiles. For example, it was reported that 14 
salivary glycine and lysine concentrations increased with aging, independent of sex 15 
(Tanaka et al., 2010). Although the effects of age were not assessed in our study, we 16 
found no significant changes in these metabolites, nor were they associated with the 17 
factors that were evaluated in this study, supporting their use as markers for aging. To 18 
 22 
generalize the results of the current study, further analyses are needed in a larger cohort 1 
of subjects/samples, particularly for the factors with a relatively small number of 2 
samples in this study e.g., collection method, the use of medications or nutritional 3 
supplements, and especially oral cavity disorders that were analyzed as a single type 4 
while different disorder may have different effects on salivary metabolite profiles. 5 
Another limitation is that we analyzed the effects of individual parameters on the 6 
salivary metabolomic profile. For example, in the analyses of sex and collection time, 7 
the age distribution was not significantly different in parametric tests (P = 0.20 for sex 8 
and P = 0.30 for collection time; Student’s t-test) but it was significantly different in 9 
non-parametric tests (P = 0.02 for sex and P = 0.03 for collection time; Mann–Whitney 10 
test). Thus, age might influence the effects of these parameters on metabolite profiles. In 11 
addition, the profiles of weakly charged metabolites that cannot be detected by CE-MS 12 
should be analyzed simultaneously (Alvarez-Sanchez et al., 2012). 13 
The parameters used in this study were assessed by questionnaire and several 14 
parameters were self-diagnosed, such as TMD. Therefore, these parameters might be 15 
inaccurate and future analyses should involve confirmation of the disease/condition by 16 
physicians or dentists to reach a more definitive conclusion. It will also be necessary to 17 
determine correlations between the saliva and blood concentrations of each metabolite 18 
 23 
(Shiiki et al., 2011) to identify the source of each molecule. To provide comprehensive 1 
datasets, we are currently developing a web-based database that incorporates all of the 2 
metabolomic concentrations and the relevant parameters that might help to understand 3 
the associations between specific phenotypes and metabolomic profiles (Sugimoto et al., 4 
2012a). 5 
 6 
4. Concluding remarks 7 
In conclusion, our study revealed that salivary metabolite profiles were associated with 8 
many physiological and environmental factors. Saliva collection method, sex, BMI, and 9 
smoking had the greatest effects on metabolite profiles. Saliva collection time also 10 
affected a greater number of salivary metabolites compared with other factors. However, 11 
age might contribute to the differences in sex and collection time. Based on these 12 
findings, the interpretation of salivary metabolomic profiles should take into account 13 
these factors and the corresponding changes in specific metabolites when using saliva to 14 
diagnose specific diseases. 15 
 16 
17 
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Figure Legends 1 
 2 
Fig. 1. Study design. To determine the effects of collection time, for example, saliva 3 
samples were collected in the morning (n = 86) and in the afternoon (n = 18). Saliva 4 
samples collected in the morning were also used to determine differences between 5 
smokers (n = 14) and non-smokers (n = 70). Because data were missing for some 6 
subjects, the total number of subjects included in the analysis of smoking status (n = 84) 7 
was less than the total number of saliva samples (n = 86). 
a,b
Saliva samples were 8 
collected in the afternoon from different subjects (n = 51). 
c
Saliva samples were 9 
collected using both methods in each subject (n = 18). 10 
 11 
Fig. 2. Principal component (PC) score plots for sex (a) (circles, females; triangles, 12 
males), BMI (b) (circles, < 18.73 kg/m
2
; triangles, 18.73–21.00 kg/m2; squares, > 21.00 13 
kg/m
2
), breakfast (c) (circles, not eaten; triangles, eaten), and smoking (d) (circles, 14 
non-smokers; triangles, smokers). The accumulated contribution ratios (%) for PC1 and 15 
PC2 were 36.5 and 53.7 in (a), 25.3 and 40.6 in (b), 23.6 and 38.5 in (c), and 24.0 and 16 
39.1 in (d), respectively. The other plots are shown in Supplementary Information Fig. 17 
2. 18 
 33 
 1 
Fig. 3. Principal components (PC) analysis of the metabolic profiles for saliva samples 2 
collected using salivettes and the passive drool method. Parallel coordinate plots of PC 3 
scores (a), loading plots (b), and concentrations of representative metabolites (c). The 4 
symbols S and P represent saliva samples collected using salivettes and the passive 5 
drool method, respectively. The accumulated contribution ratios for PC1 and PC2 were 6 
46.2% and 60.2%, respectively. 7 
 8 
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Material and Methods 
 
Instrumental parameters for capillary electrophoresis-time-of-flight-mass spectrometry 
(CE-TOFMS) 
The instrumentation and measurement conditions used for CE-TOFMS are described elsewhere (Soga et 
al., 2006; Soga et al., 2009). Briefly, cation analysis was performed using an Agilent CE capillary 
electrophoresis system, an Agilent G6220A LC/MSD TOF system, an Agilent 1100 series isocratic HPLC 
pump, a G1603A Agilent CE-MS adapter kit, and a G1607A Agilent CE-ESI-MS sprayer kit (Agilent 
Technologies, Waldbronn, Germany). Anion analysis was performed using an Agilent CE capillary 
electrophoresis system, an Agilent G6210A LC/MSD TOF system, an Agilent 1200 series isocratic HPLC 
pump, a G1603A Agilent CE-MS adapter kit, and a G1607A Agilent CE-electrospray ionization (ESI) 
source-MS sprayer kit (Agilent Technologies). For the cation and anion analyses, the CE-MS adapter kit 
includes a capillary cassette that facilitates thermostating of the capillary. The CE-ESIMS sprayer kit 
simplifies coupling of the CE system with the MS system, and is equipped with an electrospray source. 
For system control and data acquisition, we used G2201AA Agilent ChemStation software for CE and 
Agilent MassHunter software for TOF-MS. The original Agilent SST316Ti stainless steel ESI needle was 
replaced with a passivated SST316Ti stainless steel and platinum needle (passivated with 1% formic acid 
and 20% isopropanol aqueous solution at 80C for 30 min) for anion analysis. 
For cationic metabolite analysis using CE-TOFMS (Soga et al., 2006), sample separation was 
performed in fused silica capillaries (50 μm i.d. × 100 cm total length) filled with 1 mol/L formic acid as 
the reference electrolyte. Sample solutions were injected at 50 mbar for 3 s and a voltage of 30 kV was 
applied. The capillary temperature was maintained at 20C and the temperature of the sample tray was 
kept below 5C. The sheath liquid, composed of methanol/water (50% v/v) and 0.1 μmol/L hexakis 
(2,2-difluoroethoxy) phosphazene (Hexakis), was delivered at 10 μL/min. ESI-TOF-MS was conducted in 
the positive ion mode. The capillary voltage was set at 4 kV and the flow rate of nitrogen gas (heater 
temperature = 300C) was set at 10 psig. In TOF-MS, the fragmentor, skimmer and OCT RF voltages 
were 75, 50 and 125 V, respectively. Automatic recalibration of each acquired spectrum was performed 
using reference standards ([
13
C isotopic ion of protonated methanol dimer (2MeOH + H)]
+
, m/z 
66.063199) and ([protonated Hexakis (M + H)]
 +
, m/z 622.028963). Mass spectra were acquired at the rate 
of 1.5 cycles/s over a m/z range of 50–1,000. 
For anionic metabolite analysis using CE-TOFMS (Soga et al., 2009), a commercially available 
COSMO() capillary (50 μm i.d. × 110 cm, Nacalai Tesque, Kyoto, Japan), chemically coated with a 
cationic polymer, was used for separation. Ammonium acetate solution (50 mmol/L; pH 8.5) was used as 
the electrolyte for separation. Before the first use, the new capillary was flushed successively with the 
running electrolyte (pH 8.5), 50 mmol/L acetic acid (pH 3.4), and then the electrolyte again for 10 min 
each. Before each injection, the capillary was equilibrated for 2 min by flushing with 50 mM acetic acid 
 3 
(pH 3.4) and then flushed for 5 min with the running electrolyte. A sample solution (30 nL) was injected 
at 50 mbar for 30 s, and a voltage of –30 kV was applied. The capillary temperature was thermostated to 
20C and the sample tray was cooled below 5C. An Agilent 1100 series pump equipped with a 1:100 
splitter was used to deliver 10 μL/min of 5 mM ammonium acetate in 50% (v/v) methanol/water, 
containing 0.1 μM Hexakis, to the CE interface. Here, it was used as a sheath liquid surrounding the CE 
capillary to provide a stable electrical connection between the tip of the capillary and the grounded 
electrospray needle. ESI-TOF-MS was conducted in the negative ionization mode at a capillary voltage of 
3,500 V. For TOF-MS, the fragmentor, skimmer and Oct RF voltages were set at 100, 50 and 200 V, 
respectively. The flow rate of the drying nitrogen gas (heater temperature = 300C) was maintained at 10 
L/min. Automatic recalibration of each acquired spectrum was performed using reference standards ([
13
C 
isotopic ion of deprotonated acetic acid dimer (2 CH3COOH - H)]
-
, m/z 120.03841), and 
[Hexakis-deprotonated acetic acid (CH3COOH - H)]
-
, m/z 680.035541). Exact mass data were acquired at 
a rate of 1.5 spectra/s over a m/z range of 50–1,000. 
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Figure legends 
 
Supplementary Figure S1 
Principal component (PC) score plots for collection time (a) (circles, morning; triangles, afternoon), 
menstruation (b) (circles, not menstruating; triangles, menstruating), tooth brushing (c) (circles, brushed; 
triangles, not brushed), alcohol consumption (d) (circles, no consumption; triangles, regular consumption), 
use of medications (e) (circles, no use of medications; triangles, use of medications), use of nutritional 
supplements (f) (circles, no use of supplements; triangles, use of supplements), oral cavity disorders (g) 
(circles, normal; triangles, abnormal), tooth alignment disorders (h) (circles, normal; triangles, abnormal), 
carious teeth (i) (circles, no carious teeth; triangles, presence of carious teeth), and (j) TMD (circles, 
normal structure; triangles, with TMD). The accumulated contribution ratios (%) for PC1 and PC2 were 
32.0 and 44.7 in (a), 23.9 and 41.4 in (b), 24.0 and 41.1 in (c), 19.8 and 33.0 in (d), 22.6 and 38.1 in (e), 
22.5 and 38.4 in (f), 21.5 and 37.9 in (g), 21.9 and 38.0 in (h), 22.2 and 37.8 in (i), and 25.3 and 40.96 in 
(j), respectively. 
 
Supplementary Figure S2 
Concentrations of the identified salivary metabolites in subjects who did/did not use medications (a) or 
nutritional supplements (b). 
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17858 Glutathione (oxidized) 0.350 1.05 0.0156 0.0359 0.0446 1.09 × 10
-3
3.37 × 10
-3
16761 ADP 0.317 0.491 0.0257 0.0618 0.0809 7.21 × 10
-4
3.34 × 10
-3
48131 Azelate 2.06 1.85 0.221 0.218 0.108 2.13 × 10
-4
1.66 × 10
-3
15702 Terephthalate 3.95 1.89 0.546 0.381 0.138 2.14 × 10
-4
1.66 × 10
-3
30817 Urocanate 6.13 16.3 1.04 2.19 0.170 2.51 × 10
-3
4.54 × 10
-3
16010 5-Oxoproline 15.0 32.5 3.82 5.16 0.255 3.20 × 10
-4
1.85 × 10
-3
16027 AMP 1.19 2.66 0.321 0.506 0.270 9.19 × 10
-4
3.37 × 10
-3
16668 Hypotaurine 0.842 1.41 0.240 0.461 0.285 0.0376 0.0311
16345 Cysteine sulfinate 0.546 0.508 0.163 0.345 0.298 2.53 × 10
-3
4.54 × 10
-3
17822 Ser 28.1 60.9 8.91 9.17 0.317 6.48 × 10
-3
8.22 × 10
-3
17196 Asn 1.70 1.69 0.580 0.511 0.341 2.64 × 10
-3
4.54 × 10
-3
17345 GMP 0.262 0.501 0.0898 0.212 0.342 0.0167 0.0175
17750 Betaine 8.51 19.4 3.17 2.68 0.373 5.64 × 10
-3
7.67 × 10
-3
16870 Glycerophosphorylcholine 2.53 4.35 1.05 0.248 0.415 8.37 × 10
-4
3.37 × 10
-3
16857 Thr 7.78 13.5 3.50 4.89 0.450 2.27 × 10
-3
4.54 × 10
-3
6650 Malate 4.15 6.21 1.87 1.06 0.452 1.08 × 10
-3
3.37 × 10
-3
30887 Isocitrate 0.616 0.351 0.294 0.267 0.478 2.09 × 10
-3
4.54 × 10
-3
17821 Thymine 5.91 11.2 2.89 4.53 0.490 0.0455 0.0345
32805 cis -Aconitate 0.358 0.198 0.176 0.107 0.491 2.49 × 10
-4
1.66 × 10
-3
18257 Ornithine 28.9 33.1 14.2 11.1 0.493 2.45 × 10
-3
4.54 × 10
-3
17061 Gln 22.8 44.0 11.3 14.5 0.495 1.26 × 10
-3
3.44 × 10
-3
28358 Lactate 5.11 × 10
2
6.12 × 10
2
2.62 × 10
2
2.80 × 10
2 0.514 3.85 × 10
-4
1.98 × 10
-3
30915 2-Oxoglutarate 2.65 1.07 1.53 1.18 0.578 5.27 × 10
-3
7.39 × 10
-3
27570 His 9.93 9.50 6.02 4.39 0.606 4.04 × 10
-3
5.92 × 10
-3
16977 Ala 30.5 39.6 18.8 20.4 0.617 2.65 × 10
-3
4.54 × 10
-3
15960 o -Acetylcarnitine 1.53 1.23 0.955 0.442 0.622 1.08 × 10
-3
3.37 × 10
-3
32816 Pyruvate 68.6 69.1 43.3 65.1 0.631 6.58 × 10
-3
8.22 × 10
-3
18132 Phosphorylcholine 5.42 3.54 3.46 1.59 0.639 1.26 × 10
-3
3.44 × 10
-3
28631 3-Phenylpropionate 3.54 2.71 2.34 2.49 0.661 0.0294 0.0257
11851 2-Oxoisopentanoate 0.656 0.399 0.434 0.382 0.662 0.0418 0.0333
17553 Ethanolamine phosphate 76.2 64.8 50.9 34.1 0.668 1.99 × 10
-3
4.54 × 10
-3
15428 Gly 27.7 25.9 18.6 16.4 0.672 0.0120 0.0129
17295 Phe 8.24 6.51 5.55 4.30 0.674 0.0115 0.0127
16919 Creatine 33.9 45.9 23.2 29.4 0.684 7.63 × 10
-5
1.66 × 10
-3
3424 Carnitine 0.924 0.960 0.656 0.734 0.710 1.91 × 10
-4
1.66 × 10
-3
30769 Citrate 16.9 9.95 12.2 7.87 0.720 7.69 × 10
-3
9.36 × 10
-3
30794 Malonate 0.504 0.177 0.369 0.217 0.731 0.0209 0.0206
18186 Tyr 15.1 10.3 11.1 7.65 0.732 0.0245 0.0230
27596 3-Methylhistidine 0.134 0.110 0.0982 0.128 0.735 0.0463 0.0345
48430 4-Methyl-2-oxopentanoate 1.24 0.728 0.944 0.442 0.758 4.09 × 10
-3
5.92 × 10
-3
27911 N 8-Acetylspermidine 0.178 0.156 0.136 0.190 0.767 0.0179 0.0184
16953 N -Acetylaspartate 1.08 0.586 0.827 0.521 0.769 1.51 × 10
-3
3.88 × 10
-3
7307 1-Methyl-2-pyrrolidinone 26.8 8.32 20.8 4.73 0.775 4.04 × 10
-3
5.92 × 10
-3
17084 2-Hydroxyglutarate 1.08 0.629 0.881 1.13 0.813 0.0346 0.0291
15978 Glycerophosphate 6.33 3.24 5.30 2.20 0.837 0.0385 0.0312
37023 a -Aminoadipate 0.952 1.49 0.804 1.44 0.844 0.0184 0.0185
16958 b -Ala 1.14 1.34 1.02 1.25 0.893 0.0244 0.0230
28340 2AB 1.14 1.14 1.07 1.39 0.932 0.0450 0.0345
15901 Dihydrouracil 2.00 × 10
3
2.23 × 10
2
2.24 × 10
3
3.80 × 10
2 1.12 8.96 × 10
-3 0.0104
15676 Allantoin 23.9 3.67 27.5 5.12 1.15 3.77 × 10
-3
5.92 × 10
-3
16750 Guanosine 0.227 0.617 0.262 0.285 1.15 0.0278 0.0252
17363 Ru5P 0.818 1.58 0.992 0.935 1.21 0.0331 0.0284
17015 Riboflavin 0.578 0.157 0.710 0.180 1.23 3.75 × 10
-3
5.92 × 10
-3
16335 Adenosine 0.242 0.133 0.306 0.156 1.27 0.0294 0.0257
30746 Benzoate 13.9 3.52 19.5 8.70 1.40 0.0249 0.0230
15888 4-Acetylbutyrate 0.366 0.242 0.523 0.224 1.43 8.40 × 10
-3
9.96 × 10
-3
 Table S1 Effects of collection method
Salivettes
(n = 18)
Possive drool method
 (n = 18) FC P -valueChEBI q -valueName
506227 N -Acetylglucosamine 2.40 2.35 4.41 5.98 1.84 5.96 × 10
-3
7.88 × 10
-3
17797 R5P 0.264 0.406 0.608 0.811 2.30 0.0455 0.0345
15746 Spermine 0.0962 0.262 0.242 0.565 2.52 1.95 × 10
-3
4.54 × 10
-3
18127 Cadaverine 2.74 5.58 7.40 22.4 2.70 0.0106 0.0119
16610 Spermidine 0.487 1.02 1.38 2.59 2.82 2.51 × 10
-4
1.66 × 10
-3
17562 Cytidine 0.0683 0.0749 0.237 0.184 3.47 2.51 × 10
-4
1.66 × 10
-3
Mean SD Mean SD
- Syringate 1.59 0.118 0.00 0.00 0.00 1.21 × 10
-11
7.10 × 10
-10
64277 7,8-Dihydrobiopterin 10.8 14.7 1.22 3.60 0.113 2.36 × 10
-4
1.73 × 10
-3
17869 6-Hydroxyhexanoate 0.315 0.250 0.0489 0.142 0.155 7.69 × 10
-5
1.05 × 10
-3
16831 3-Hydroxy-3-methylglutarate 0.0917 0.0851 0.0201 0.0639 0.219 1.22 × 10
-4
1.08 × 10
-3
17797 R5P 0.720 0.402 0.264 0.406 0.367 3.27 × 10
-5
6.39 × 10
-4
15946 Fluctose 6-phosphate 0.403 0.286 0.173 0.176 0.429 1.07 × 10
-3
4.83 × 10
-3
48928 6-Phosphogluconate 0.253 0.218 0.117 0.228 0.461 1.78 × 10
-3
7.05 × 10
-3
30915 2-Oxoglutarate 5.27 3.61 2.65 1.07 0.502 1.29 × 10
-4
1.08 × 10
-3
1178 2-Isopropylmalate 0.218 0.138 0.114 0.0493 0.522 8.96 × 10
-5
1.05 × 10
-3
17562 Cytidine 0.123 0.0900 0.0683 0.0749 0.555 0.0461 0.0696
30887 Isocitrate 0.988 0.531 0.616 0.351 0.623 7.80 × 10
-3 0.0240
17533 N -Acetylglutamate 0.0700 0.0525 0.0448 0.0564 0.639 0.0433 0.0696
16576 Ala-Ala 0.184 0.138 0.119 0.176 0.649 0.0289 0.0576
16682 N-Acetyl-b -alanine 0.214 0.154 0.151 0.335 0.704 0.0110 0.0269
16695 UMP 0.708 1.98 0.508 1.22 0.718 0.0404 0.0696
18021 PEP 0.419 0.270 0.312 0.332 0.744 7.14 × 10
-3 0.0232
17015 Riboflavin 0.754 0.222 0.578 0.157 0.767 1.81 × 10
-3
7.05 × 10
-3
6650 Malate 5.22 3.49 4.15 6.21 0.794 6.05 × 10
-4
3.55 × 10
-3
17672 Carbamoylphosphate 38.4 8.24 32.1 7.53 0.836 0.0106 0.0269
16446 N -Acetylglucosamine 1-phosphate 0.326 0.327 0.282 0.623 0.868 9.64 × 10
-3 0.0269
15901 Dihydrouracil 2.21 × 10
3
3.53 × 10
2
2.00 × 10
3
2.23 × 10
2 0.908 4.58 × 10
-3 0.0168
15966 Glu 14.9 7.60 14.5 19.8 0.968 0.0163 0.0364
18012 Fumarate 0.798 0.396 0.778 1.07 0.975 0.0103 0.0269
17363 Ru5P 0.830 0.542 0.818 1.58 0.985 0.0300 0.0576
17858 Glutathione (oxidized) 0.349 0.436 0.350 1.05 1.00 0.0437 0.0696
15741 Succinate 15.0 15.5 15.6 27.7 1.03 0.0314 0.0576
17794 3PG 1.54 1.04 1.66 2.97 1.08 0.0139 0.0325
15784 N -Acetylglucosamine 6-phosphate 0.173 0.163 0.192 0.574 1.11 0.0174 0.0364
17497 Glycolate 9.67 3.35 10.9 2.45 1.12 0.0173 0.0364
28837 Octanoate 0.629 0.249 0.738 0.193 1.17 7.05 × 10
-3 0.0232
15721 S7P 0.299 0.236 0.360 1.20 1.20 1.06 × 10
-3
4.83 × 10
-3
18406 5-Aminoimidazole-4-carboxamide ribotide 0.441 0.133 0.548 0.153 1.24 3.00 × 10
-4
1.95 × 10
-3
4170 G6P 1.73 1.28 2.23 5.59 1.29 9.55 × 10
-3 0.0269
15676 Allantoin 18.1 5.09 23.9 3.67 1.32 1.15 × 10
-6
3.37 × 10
-5
- Cysteine-glutathione disulphide 0.234 0.267 0.362 1.18 1.54 0.0315 0.0576
17460 Lipoamide 0.278 0.208 0.439 0.254 1.58 1.06 × 10
-3
4.83 × 10
-3
18257 Ornithine 16.7 14.6 28.9 33.1 1.73 0.0368 0.0653
16345 Cysteine sulfinate 0.316 0.424 0.546 0.508 1.73 0.0463 0.0696
32980 3-(4-Hydroxyphenyl)propionate 1.59 2.05 3.11 5.21 1.96 0.0447 0.0696
Mean SD Mean SD
16870 Glycerophosphorylcholine 1.84 0.652 0.00 0.00 0.00 3.66 × 10
-11
1.79 × 10
-10
18086 Indole-3-acetaldehyde 7.24 1.16 0.00 0.00 0.00 3.68 × 10
-11
1.79 × 10
-10
18406 5-Aminoimidazole-4-carboxamide ribotide 0.504 0.126 0.00 0.00 0.00 3.69 × 10
-11
1.79 × 10
-10
17015 Riboflavin 0.880 0.375 0.00 0.00 0.00 3.69 × 10
-11
1.79 × 10
-10
17084 2-Hydroxyglutarate 1.44 1.33 0.00 0.00 0.00 3.71 × 10
-11
1.79 × 10
-10
28179 Benzamide 24.3 12.3 0.00 0.00 0.00 3.71 × 10
-11
1.79 × 10
-10
7971 5-Methoxy-3-indoleaceate 1.09 2.13 0.00 0.00 0.00 3.71 × 10
-11
1.79 × 10
-10
- Mucate 0.266 0.160 0.00 0.00 0.00 2.17 × 10
-9
4.88 × 10
-9
17858 Glutathione (oxidized) 0.207 0.264 0.00 0.00 0.00 8.35 × 10
-8
1.13 × 10
-7
P -valueChEBI
ChEBI Name
Morning (n = 86) Afternoon (n = 18)
FC P -value
Male (n = 27)
FC
Table S3 Effects of sex (female vs male)
Name
Female (n = 24)
q -value
q -value
Table S2  Effects of collection time (morning vs afternoon)
- Cysteine-glutathione disulphide 0.227 0.209 0.00 0.00 0.00 8.35 × 10
-8
1.13 × 10
-7
16761 ADP 0.298 0.316 0.00 0.00 0.00 8.35 × 10
-8
1.13 × 10
-7
17859 Glutarate 0.501 1.36 0.00 0.00 0.00 6.06 × 10
-6
5.53 × 10
-6
16668 Hypotaurine 0.614 0.660 0.00 0.00 0.00 1.61 × 10
-5
1.23 × 10
-5
16796 Melatonin 0.191 0.201 0.00 0.00 0.00 4.15 × 10
-5
2.86 × 10
-5
30831 2-Oxobutyrate 4.06 8.39 0.0412 0.214 0.0101 4.64 × 10
-9
9.20 × 10
-9
15702 Terephthalate 3.72 1.60 0.0785 0.0591 0.0211 1.02 × 10
-9
2.86 × 10
-9
48131 Azelate 1.73 1.02 0.0648 0.127 0.0374 2.44 × 10
-10
8.24 × 10
-10
27596 3-Methylhistidine 0.126 0.139 9.50 × 10
-3 0.0494 0.0757 1.10 × 10
-6
1.24 × 10
-6
17748 Thymidine 2.52 0.579 0.221 0.800 0.0877 8.95 × 10
-9
1.68 × 10
-8
15746 Spermine 0.0665 0.0665 7.33 × 10
-3 0.0381 0.110 6.43 × 10
-5
4.25 × 10
-5
16345 Cysteine sulfinate 0.627 0.484 0.0732 0.284 0.117 2.55 × 10
-5
1.81 × 10
-5
16027 AMP 1.04 1.08 0.124 0.284 0.120 1.40 × 10
-6
1.52 × 10
-6
17553 Ethanolamine phosphate 66.2 20.4 14.8 17.4 0.223 1.72 × 10
-8
2.64 × 10
-8
32816 Pyruvate 62.5 47.1 16.0 18.3 0.256 6.60 × 10
-7
7.67 × 10
-7
7307 1-Methyl-2-pyrrolidinone 25.0 7.93 6.51 5.41 0.260 1.40 × 10
-8
2.37 × 10
-8
16919 Creatine 30.7 14.6 8.32 3.30 0.271 1.46 × 10
-9
3.52 × 10
-9
27911 N 8-Acetylspermidine 0.150 0.0787 0.0437 0.129 0.292 4.41 × 10
-7
5.72 × 10
-7
28837 Octanoate 0.741 0.162 0.218 0.635 0.294 5.31 × 10
-7
6.64 × 10
-7
15901 Dihydrouracil 2.35 × 10
3
6.54 × 10
2
7.00 × 10
2
1.99 × 10
2 0.297 1.30 × 10
-9
3.37 × 10
-9
15676 Allantoin 24.0 4.41 8.69 3.25 0.362 2.31 × 10
-9
4.88 × 10
-9
17672 Carbamoylphosphate 33.4 10.6 12.4 14.8 0.372 8.69 × 10
-6
7.52 × 10
-6
37023 a -Aminoadipate 0.821 0.408 0.336 0.475 0.409 5.94 × 10-4 3.06 × 10-4
15956 Biotin 0.296 0.150 0.123 0.141 0.416 1.99 × 10
-4
1.20 × 10
-4
28358 Lactate 2.31 × 10
2
1.12 × 10
2 96.4 68.3 0.417 1.89 × 10
-6
1.95 × 10
-6
18132 Phosphorylcholine 5.21 2.21 2.21 2.22 0.423 1.81 × 10
-5
1.33 × 10
-5
16953 N -Acetylaspartate 1.54 1.13 0.658 0.331 0.427 4.95 × 10
-4
2.69 × 10
-4
30915 2-Oxoglutarate 3.78 2.33 1.64 3.47 0.435 2.59 × 10
-4
1.53 × 10
-4
29069 Phthalate 0.0841 0.0878 0.0397 0.0623 0.472 0.0495 0.0174
18021 PEP 0.463 0.275 0.219 0.312 0.472 6.00 × 10
-4
3.06 × 10
-4
32805 cis -Aconitate 0.363 0.169 0.172 0.179 0.473 2.54 × 10
-3
1.19 × 10
-3
18095 Hydroxyproline 0.873 0.537 0.432 0.431 0.495 1.42 × 10
-3
6.92 × 10
-4
15960 o -Acetylcarnitine 1.68 0.780 0.843 0.441 0.501 1.81 × 10
-5
1.33 × 10
-5
11851 2-Oxoisopentanoate 0.679 0.369 0.345 0.858 0.508 1.19 × 10
-4
7.43 × 10
-5
16446 N -Acetylglucosamine 1-phosphate 0.251 0.167 0.135 0.363 0.539 3.01 × 10
-4
1.72 × 10
-4
15946 Fluctose 6-phosphate 0.370 0.197 0.208 0.352 0.560 6.53 × 10
-3
2.74 × 10
-3
4324 3-Hydroxybutyrate 4.71 7.21 2.64 1.83 0.561 0.0452 0.0162
16695 UMP 0.510 0.518 0.286 0.458 0.561 0.0190 7.29 × 10
-3
16108 DHAP 3.68 1.39 2.08 1.62 0.566 8.92 × 10
-4
4.43 × 10
-4
18295 Histamine 0.374 0.527 0.216 0.492 0.577 0.0166 6.50 × 10
-3
17361 CMP 0.0965 0.0870 0.0573 0.176 0.594 5.19 × 10
-3
2.30 × 10
-3
30769 Citrate 18.1 10.3 10.9 8.35 0.604 2.30 × 10
-3
1.09 × 10
-3
15891 Taurine 57.8 24.3 40.1 24.5 0.694 6.58 × 10
-3
2.74 × 10
-3
17794 3PG 1.69 0.706 1.26 1.21 0.746 5.51 × 10
-3
2.41 × 10
-3
17460 Lipoamide 0.549 0.674 0.424 0.941 0.772 0.0130 5.27 × 10
-3
16411 Indole-3-acetate 1.08 1.40 0.859 2.16 0.797 6.14 × 10
-3
2.64 × 10
-3
17497 Glycolate 10.7 1.79 8.64 3.09 0.806 5.69 × 10
-4
3.00 × 10
-4
17533 N -Acetylglutamate 0.0723 0.0367 0.0695 0.137 0.961 9.48 × 10
-3
3.90 × 10
-3
16737 Creatinine 2.84 0.880 3.93 1.43 1.38 2.92 × 10
-3
1.32 × 10
-3
16958 b -Ala 1.01 0.448 1.48 0.851 1.46 0.0139 5.59 × 10-3
1178 2-Isopropylmalate 0.159 0.0746 0.247 0.161 1.56 0.0222 8.43 × 10
-3
16235 Guanine 0.769 0.404 1.51 1.37 1.96 0.0495 0.0174
30794 Malonate 0.396 0.159 0.865 0.291 2.18 1.64 × 10
-8
2.63 × 10
-8
- 5-Oxoproline 3.84 2.81 8.70 7.55 2.26 0.0169 6.56 × 10
-3
15354 Choline 3.92 2.23 8.94 5.57 2.28 4.63 × 10
-4
2.56 × 10
-4
18019 Lys 19.2 12.8 45.1 45.0 2.35 0.0300 0.0112
17012 N -Acetylneuraminate 15.9 11.2 41.1 34.6 2.58 2.69 × 10
-3
1.23 × 10
-3
16708 Adenine 0.448 0.309 1.19 1.25 2.65 6.18 × 10
-3
2.64 × 10
-3
15741 Succinate 9.03 5.22 24.3 20.4 2.69 2.61 × 10
-3
1.21 × 10
-3
17053 Asp 6.54 2.35 18.2 14.6 2.78 9.20 × 10
-6
7.57 × 10
-6
17431 Agmatine 0.0578 0.0466 0.170 0.210 2.95 0.0444 0.0161
18101 4-Hydroxyphenylacetate 2.70 4.48 8.18 11.0 3.03 0.0334 0.0124
16610 Spermidine 0.402 0.320 1.27 1.70 3.15 0.0414 0.0152
15966 Glu 13.5 8.75 43.4 55.1 3.20 7.29 × 10
-4
3.67 × 10
-4
16467 Arg 9.00 2.75 28.9 20.1 3.21 6.75 × 10
-6
6.00 × 10
-6
48928 6-Phosphogluconate 0.171 0.231 0.557 0.537 3.27 5.59 × 10
-4
3.00 × 10
-4
17368 Hypoxanthine 1.55 0.973 5.83 5.65 3.77 1.32 × 10
-4
8.09 × 10
-5
15428 Gly 23.2 11.6 92.0 83.7 3.96 2.57 × 10
-5
1.81 × 10
-5
15727 Carnosine 0.115 0.290 0.469 0.434 4.07 2.69 × 10
-6
2.67 × 10
-6
17822 Ser 7.77 4.10 31.7 24.5 4.08 1.48 × 10
-5
1.16 × 10
-5
17768 N -Acetylputrescine 1.04 0.694 5.06 7.64 4.87 0.0145 5.75 × 10
-3
16349 Citrulline 4.61 2.82 26.2 33.1 5.68 1.79 × 10
-3
8.61 × 10
-4
15603 Leu 2.79 1.21 16.0 21.5 5.72 9.68 × 10
-5
6.16 × 10
-5
30817 Urocanate 0.942 1.54 5.49 5.14 5.82 1.25 × 10
-5
1.00 × 10
-5
17363 Ru5P 0.825 0.406 5.09 4.91 6.17 5.96 × 10
-7
7.18 × 10
-7
17203 Pro 18.8 13.5 1.18 × 10
2
1.25 × 10
2 6.29 3.49 × 10
-4
1.96 × 10
-4
506227 N -Acetylglucosamine 3.14 2.38 21.4 18.6 6.82 9.19 × 10
-6
7.57 × 10
-6
17562 Cytidine 0.0787 0.0807 1.05 0.828 13.4 1.19 × 10
-8
2.11 × 10
-8
17191 Ile 0.0890 0.330 6.60 9.47 74.1 9.99 × 10
-10
2.86 × 10
-9
16643 Met 0.0354 0.0873 2.88 5.55 81.4 2.81 × 10
-4
1.63 × 10
-4
- Gly-Leu 2.96 × 10
-3 0.0145 0.918 1.35 3.10 × 10
2
6.90 × 10
-5
4.48 × 10
-5
- Syringate 0.00 0.00 1.71 0.0913 N.A.6.49 × 10
-11
2.74 × 10
-10
39708 8-Anilino-1-naphthalene sulfonate 0.00 0.00 0.330 0.182 N.A.1.11 × 10
-10
4.17 × 10
-10
35697 trans-Cinnamate 0.00 0.00 0.869 1.14 N.A. 1.91 × 10
-6
1.95 × 10
-6
47977 Glucosamine 0.00 0.00 3.02 4.13 N.A. 4.70 × 10
-6
4.40 × 10
-6
15940 Nicotinate 0.00 0.00 2.10 2.46 N.A. 4.70 × 10
-6
4.40 × 10
-6
- Isopropanolamine 0.00 0.00 0.324 0.413 N.A. 5.82 × 10
-5
3.93 × 10
-5
Mean SD Mean SD
18295 Histamine 0.114 0.160 0.255 0.360 0.448 0.0170 0.215
32980 3-(4-Hydroxyphenyl)propionate 1.03 1.26 2.02 2.48 0.509 0.0296 0.263
18127 Cadaverine 1.32 1.41 2.50 2.62 0.526 0.0190 0.220
28631 3-Phenylpropionate 2.40 3.87 4.07 3.99 0.591 4.78 × 10
-3 0.215
17148 Putrescine 12.7 13.0 20.6 14.7 0.617 0.0237 0.235
6128 2-Hydroxy-4-methylpentanoate 0.425 0.279 0.688 0.530 0.618 9.81 × 10
-3 0.215
15887 5-Aminovalerate 74.2 1.05 × 10
2
1.19 × 10
2 93.3 0.623 8.68 × 10
-3 0.215
18257 Ornithine 12.5 10.8 18.3 14.2 0.680 0.0439 0.287
1941 g -Butyrobetaine 0.754 0.692 1.10 0.713 0.687 9.04 × 10-3 0.215
32978 3-Phenyllactate 0.427 0.354 0.596 0.337 0.717 0.0135 0.215
30772 Butanoate 13.3 12.8 18.3 13.0 0.725 0.0336 0.275
15611 Sarcosine 2.53 1.74 3.48 2.23 0.726 0.0453 0.287
545959 Homovanillate 1.43 1.13 1.94 1.15 0.738 0.0170 0.215
30776 Hexanoate 6.93 4.92 8.47 4.43 0.818 0.0385 0.276
16199 Urea 4.95 × 10
2
1.73 × 10
2
4.76 × 10
2
1.98 × 10
2 1.04 0.0303 0.263
6650 Malate 6.35 3.56 4.53 2.22 1.40 0.0398 0.276
18012 Fumarate 0.997 0.492 0.707 0.303 1.41 0.0163 0.215
16870 Glycerophosphorylcholine 1.98 1.45 1.38 0.531 1.44 0.0146 0.215
17196 Asn 1.74 0.972 1.20 0.809 1.46 0.0219 0.234
15946 Fluctose 6-phosphate 0.551 0.364 0.368 0.249 1.50 0.0382 0.276
16027 AMP 1.51 1.44 0.793 0.705 1.91 0.0484 0.293
16761 ADP 0.387 0.462 0.169 0.234 2.30 0.0158 0.215
Mean SD Mean SD
30831 2-Oxobutyrate 4.12 4.41 2.62 4.13 0.635 0.0449 0.816
4324 3-Hydroxybutyrate 5.00 4.25 3.22 2.77 0.686 9.42 × 10
-3 0.816
BMI ≥ 18.73 kg/m
2
(n = 45) FC
BMI < 21.00 kg/m
2
(n = 45)ChEBI Name
BMI ≥ 21.00 kg/m
2
 (n = 22)
Table S4 Effect of BMI (< 18.73 kg/m
2
 vs ≥ 18.73 kg/m2)
Table S5 Effect of BMI (< 21.00 kg/m
2
 vs ≥ 21.00 kg/m
2
)
Name
FC P -value
ChEBI
BMI < 18.73 kg/m
2
(n = 22)
q -value
P -value q -value
11851 2-Oxoisopentanoate 1.06 0.436 0.752 0.287 0.788 0.0293 0.816
15888 4-Acetylbutyrate 0.417 0.137 0.349 0.124 0.875 0.0459 0.816
Mean SD Mean SD
17460 Lipoamide 0.281 0.203 0.153 0.182 0.545 0.0342 0.504
11955 4-Amino-3-hydroxybutyrate 0.0410 0.110 0.205 0.259 5.00 3.36 × 10
-3 0.314
Mean SD Mean SD
30817 Urocanate 7.25 12.7 1.23 1.70 0.170 5.64 × 10
-5
7.94 × 10
-3
- 5-Oxoproline 18.2 20.9 5.65 4.71 0.310 6.21 × 10
-4 0.0291
17822 Ser 32.0 41.4 10.0 6.21 0.314 1.15 × 10
-3 0.0403
64277 7,8-Dihydrobiopterin 23.6 28.7 8.25 8.34 0.349 9.09 × 10
-3 0.153
28358 Lactate 6.20 × 10
2
6.25 × 10
2
2.27 × 10
2
1.32 × 10
2 0.366 3.22 × 10
-4 0.0226
- Methionine sulfoxide 0.110 0.126 0.0444 0.0842 0.405 0.0275 0.322
16643 Met 0.418 0.420 0.176 0.152 0.420 0.0126 0.177
30833 Adipate 0.171 0.159 0.0813 0.111 0.476 0.0339 0.341
16857 Thr 7.98 7.32 3.96 2.50 0.496 0.0218 0.279
17196 Asn 2.17 1.41 1.24 0.768 0.574 9.79 × 10
-3 0.153
15603 Leu 6.61 4.84 3.80 2.10 0.575 9.71 × 10
-3 0.153
48131 Azelate 2.74 1.71 1.69 0.876 0.616 7.75 × 10
-3 0.153
15702 Terephthalate 5.01 1.19 3.94 1.61 0.786 3.36 × 10
-3 0.0947
32980 3-(4-Hydroxyphenyl)propionate 1.32 2.81 1.64 1.89 1.24 0.0383 0.360
- Mucate 0.172 0.160 0.312 0.202 1.81 0.0303 0.328
Mean SD Mean SD
30883 Adipate 0.124 0.115 0.0658 0.107 0.529 0.0410 0.978
15888 4-Acetylbutyrate 0.446 0.157 0.357 0.167 0.801 0.0265 0.978
18132 Phosphorylcholine 4.44 2.30 5.24 1.97 1.18 0.0455 0.978
17562 Cytidine 0.0886 0.0760 0.125 0.0812 1.41 0.0469 0.978
Mean SD Mean SD
32362 Heptanoate 0.218 0.144 0.111 0.139 0.509 0.0221 0.299
16695 UMP 0.676 2.15 0.893 1.08 1.32 0.0364 0.299
17368 Hypoxanthine 1.57 1.14 2.12 1.17 1.35 0.0476 0.299
16682 N -Acetyl-b-alanine 0.199 0.152 0.299 0.141 1.51 0.0424 0.299
4170 G6P 1.60 1.19 2.42 1.55 1.52 0.0476 0.299
17345 GMP 0.199 0.245 0.312 0.229 1.57 0.0406 0.299
16610 Spermidine 0.331 0.265 0.552 0.329 1.67 0.0129 0.257
16027 AMP 0.912 0.994 1.60 1.12 1.76 0.0267 0.299
17821 Thymine 1.81 2.51 3.51 3.10 1.94 0.0340 0.299
28931 3'-AMP 0.137 0.204 0.269 0.162 1.96 5.23 × 10
-3 0.257
16761 ADP 0.207 0.324 0.433 0.363 2.10 0.0124 0.257
16264 UDP-N -acetylglucosamine 0.110 0.199 0.272 0.271 2.47 9.02 × 10
-3 0.257
30817 Urocanate 1.49 1.98 5.78 13.1 3.87 0.0279 0.299
17688 Nicotine 2.92 × 10
-3 0.0177 0.402 0.287 1.38 × 10
2
1.34 × 10
-14
1.34 × 10
-12
Mean SD Mean SD
17431 Agmatine 0.0403 0.0425 0.0232 0.0382 0.576 0.0490 0.983
Table S10 Effects of alcohol consumption
q -value
ChEBI Name
ChEBI Name
No consumption
 (n = 36)
Regular consumption
 (n = 50) FC P -value
q -value
ChEBI Name
Not brushed (n = 19) Brushed (n = 53)
FC
Table S8 Effects of tooth brushing
FC P -value
q -value
ChEBI Name
Not eaten (n = 72) Eaten (n = 20)
Non-smoker (n = 70) Smoker (n = 14)
FC P -value q -value
P -value
P -value
Table S7 Effects of eating breakfast
ChEBI Name
Not menstruating
(n = 63)
Menstruating
(n = 9) FC
Table S6 Effects of menstruation
q -value
Table S9 Effects of smoking
506227 N -Acetylglucosamine 3.78 3.93 2.23 1.83 0.590 0.0198 0.983
17012 N -Acetylneuraminate 17.1 12.1 12.5 10.8 0.733 0.0239 0.983
- Syringate 1.57 0.123 1.62 0.105 1.03 0.0246 0.983
Mean SD Mean SD
32383 6-Hydroxyhexanoate 0.358 0.404 0.0718 0.144 0.201 0.0267 0.958
29069 Phthalate 0.174 0.499 0.146 5.66 × 10
-3 0.840 0.0249 0.958
Mean SD Mean SD
15946 Fluctose 6-phosphate 0.413 0.225 0.210 0.164 0.509 0.0268 0.738
15966 Glu 14.5 6.75 8.91 3.90 0.615 0.0345 0.738
16108 DHAP 3.00 1.57 1.87 0.809 0.623 0.0420 0.738
28340 2AB 0.986 0.285 0.637 0.120 0.646 8.84 × 10
-3 0.415
18295 Histamine 0.179 0.368 0.253 0.176 1.41 0.0244 0.738
32362 Heptanoate 0.189 0.155 0.338 0.0993 1.79 0.0376 0.738
7548 1-Methylhistamine 0.0125 0.0348 0.0301 0.0193 2.41 8.64 × 10
-3 0.415
17859 Glutarate 0.0770 0.0431 0.546 0.712 7.09 1.67 × 10
-3 0.234
Mean SD Mean SD
7548 1-Methylhistamine 0.0117 0.0359 0.0203 0.0254 1.74 0.0154 0.822
16414 Val 3.63 1.66 4.93 2.31 1.36 0.0344 0.822
17394 N -g -Ethylglutamine 0.0499 0.108 0.110 0.132 2.19 0.0390 0.822
Mean SD Mean SD
17562 Cytidine 0.132 0.0808 0.0795 0.0643 0.613 0.0186 0.968
15676 Allantoin 18.9 4.50 17.1 5.00 0.926 0.0470 0.968
16750 Guanosine 0.101 0.0647 0.0609 0.0661 1.07 0.0260 0.968
4324 3-Hydroxybutyrate 3.88 4.26 5.04 3.02 1.19 0.0117 0.968
Mean SD Mean SD
16010 5-Oxoproline 0.618 0.758 0.481 0.853 0.848 0.0289 0.880
17968 Butanoate 12.5 8.39 20.5 16.5 1.64 4.84 × 10
-3 0.778
17858 Glutathione (oxidized) 0.249 0.397 0.441 0.403 1.77 0.0199 0.880
30854 Indole-3-acetate 0.151 0.478 0.571 0.992 3.80 0.0203 0.880
28179 Benzamide 0.151 8.15 24.7 12.7 1.64 × 10
2 0.0299 0.880
Mean SD Mean SD
6650 Malate 3.79 1.80 5.36 2.50 1.23 0.0251 0.767
16977 Ala 17.0 9.27 23.0 8.42 1.33 6.77 × 10
-3 0.599
28358 Lactate 1.59 × 10
2 71.4 2.50 × 10
2
1.42 × 10
2 1.35 0.0146 0.767
17858 Glutathione (oxidized) 0.216 0.250 0.434 0.405 1.53 0.0401 0.767
17821 Thymine 0.655 1.44 2.61 2.39 1.68 1.66 × 10
-3 0.294
ChEBI Name
None
(n = 13)
P -value
Normal (n = 25) Abnormal (n = 22)
FC P -value
Table S16 Effects of TMD
ChEBI
Abnormal (n = 23)
FC
Table S11 Effects of the use of medications
Table S13 Effects of oral cavity disorders
P -value
Name
FC P -value q -value
With carious teesh
(n = 67)
q -value
q -value
Table S14 Effects of tooth alignment disorders
ChEBI Name
Normal (n = 25) Abnormal (n = 22)
FC
ChEBI Name
Normal (n = 31)
q -valueChEBI Name
Not used (n = 44)
q -value
Used (n = 5)
FC P -value
ChEBI Name
Not used (n = 49) Used (n = 4)
FC P -value q -value
Table S12 Effects of the use of nutritional supplements
Table S15 Effects of dental caries
The medications included (1) vitamin drops (containing ascorbic acid and pantothenic acid), (2) theodur, (3) theophylline and
olopatadine, (4) mecobalamin, and (5) furosemide.
The saliva donors took vitamin drops (n  = 3), black vinegar (n  = 1), and flavin adenine dinucleotide sodium and pyridoxal
phosphate hydrate (n  = 1).
